Pfizer Inc. (NYSE:PFE - Get Free Report) Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Pfizer Stock Down 0.6 %
NYSE PFE traded down $0.15 during mid-day trading on Friday, hitting $25.50. The company's stock had a trading volume of 33,055,417 shares, compared to its average volume of 37,577,760. The company's 50 day simple moving average is $26.28 and its 200 day simple moving average is $27.58. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $144.48 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 0.64 and a beta of 0.64.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. Pfizer's revenue was up 24.7% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.75%. This is an increase from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's payout ratio is currently 121.99%.
Wall Street Analysts Forecast Growth
Several research firms recently commented on PFE. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $31.92.
Read Our Latest Stock Analysis on Pfizer
Hedge Funds Weigh In On Pfizer
A number of hedge funds have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the 4th quarter worth $28,000. Gladius Capital Management LP boosted its holdings in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter worth about $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
